Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. - Scott,R.; Wu,M.; Sanchez,M.; Stein,P. (Int J Clin Pract, 2007)